LANSING, MI — (Marketwire) — 08/08/11 — Kraig Biocraft Laboratories, Inc. (KBLB) announced that researchers working with the Company recently completed the second round of micro-insertions using zinc finger technology. The use of the zinc finger technology in the second round is designed to further enhance Kraig’s previously disclosed Monster Silk polymers.
“This round of micro-insertions is focused on further modifying and advancing the capabilities of our ‘Monster Silk’ caterpillars,” said CEO Kim Thompson. “In the second round, the zinc finger technology is being used to modify one of the company’s transgenic lines of silk worm that are already producing recombinant spider silk. This work represents a significant step forward from our first round of zinc finger micro-insertions.
“We are so confident in the technology,” continued Thompson, “that we advanced to the second round of micro-insertions even while we are still awaiting a definitive report on the first round.”
The current second round is focused on two objectives: 1) modifying the profile of the expressed proteins in the previously disclosed “Monster Silk” fiber, and 2) potentially creating a new recombinant silk platform technology.
“We are very happy to see this work progressing so quickly,” said Thompson. “As I have previously noted, we are monitoring the results of round one, and now of round two, very closely. We are very optimistic that we will be able to announce results from the first round in early Fall, and results from the second round, in approximately the middle to late Fall.”
In April, Kraig entered into an agreement with Sigma-Aldrich to use Sigma’s powerful zinc finger technology to accelerate Kraig’s scientific research and product development. The zinc fingers are an effective genetic engineering technology that the Company is using to create the next generation of biomaterials, including recombinant spider silks, for the textile and technical textile markets.
About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information, please visit www.KraigLabs.com.
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
Contact:
Ben Hansel, Hansel Capital, LLC
(720) 288-8495